Coming to America? Novartis subsidiary launches first biosimilar product in the US

Update - Wholesale cost of Zarxio will be 15% less than Amgen's Neupogen

Biosimilars land in the US as Sandoz launches Zarxio

By Dan Stanton

Sandoz has launched Zarxio, the first biosimilar in the US, despite a last ditch effort to block the copycat version of Neupogen by Amgen.

Novo opts to build US API capacity for semaglutide rather than outsource

To supply the Dane: Novo expects First API batch in 2020

By Gareth Macdonald

Novo Nordisk has confirmed it will build an API plant in the US, telling this publication a desire to have manufacturing capacity in the key market for its oral diabetes candidate, semaglutide, drove the decision.

The agreement was initially expected to be forged by 2015.

Dispatches from InformEx

US-EU trade agreement not likely until 2017, SOCMA says

By Zachary Brennan

Pharmaceutical and chemical manufacturers may have to wait until 2017 to see the benefits of the Transatlantic Trade and Investment Partnership, VP of SOCMA (Society of Chemical Manufacturers and Affiliates) told attendees at InformEx in New Orleans.

Sanofi headquarters

Sanofi to hike biologics CapEx in 2015

By Gareth Macdonald

Sanofi will invest in biologics and vaccine manufacturing capacity in 2015 to sustain product launches and ease constraints that impacted its Sanofi Pasteur division in the past few years.

An insulin model (Picture credit: Novo Nordisk).

Novo Nordisk defiant despite $90,000 disclosure fine

By Fiona Barry

Novo Nordisk wants “a political debate” and changes to financial disclosure laws after Danish authorities fined it $90,000 for not immediately telling investors the US FDA had rejected Tresiba and Ryzodeg in 2013.


Follow us


View more


Featured Suppliers

All suppliers